Dr. Cloughesy is a professor of neurology at the David Geffen School of Medicine at UCLA. He also serves as Director of UCLA’s Neuro-Oncology Program, Co-Director of the UCLA Brain Tumor Center and Director of the Henry Singleton Brain Cancer Research Program.

Dr. Cloughesy is board certified in neurology and clinical neurophysiology and has the UCNS Neuro-Oncology Certification.

His research includes therapeutic, imaging, translational and basic investigations. Dr. Cloughesy’s experience with clinical trials includes therapeutic approaches such as small molecule inhibitors, antibodies, antibody drug conjugates, chemotherapies, vaccines, viral gene transfer and immune check point therapies. His focus on clinical trials in brain cancer involves novel clinical trial design, incorporation of biomarkers and development of new biomarkers. He provided principal leadership for the accelerated approval and the conversion to full approval of the drug bevacizumab for recurrent glioblastoma.

Dr. Cloughesy has developed a brain cancer bioinformatics database which combines clinical outcomes, imaging, and molecular analysis to foster and enhance translational research. He has authored or co-authored more than 300 peer-reviewed articles on brain cancer and has a Google Scholar H index of 98.

Dr. Cloughesy received his B.A. degree with honors from the University of California, Santa Barbara, and his M.D. from Tulane University. He completed his neurology residency and fellowships in clinical neurophysiology at University of California, Los Angeles.